Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Autologous and Antigen-specific Cell-based Therapy of Vitamin D3-treated and Myelin-derived Peptide Loaded Tolerogenic Dendritic Cells in Subjects With Progressive Forms of Multiple Sclerosis: a Phase IIa, Open-label, Self-controlled, Multi-center Clinical Trial

NCT07020715 is registered in ClinicalTrials.gov with University Hospital, Antwerp as lead sponsor.

NCT NCT07020715
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07020715 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Autologous and Antigen-specific Cell-based Therapy of Vitamin D3-treated and Myelin-derived Peptide Loaded Tolerogenic Dendritic Cells in Subjects With Progressive Forms of Multiple Sclerosis: a Phase IIa, Open-label, Self-controlled, Multi-center Clinical Trial
Lead sponsor
University Hospital, Antwerp
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
October 30, 2029
Enrollment
14 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis